#USA #Lund #TFS HealthScience #Oncomatryx #OMTX705

Promising Collaboration in Cancer Research

TFS HealthScience, a prominent global Contract Research Organization (CRO), is enhancing its collaborative efforts with Oncomatryx, a leading biopharmaceutical company. This strengthened partnership focuses on a Phase Ib clinical trial evaluating OMTX705, an innovative antibody-drug conjugate (ADC) that targets cancer-associated fibroblasts, particularly for patients suffering from advanced or metastatic pancreatic adenocarcinoma.

Pancreatic cancer remains one of the deadliest forms of cancer worldwide, with the World Cancer Research Foundation reporting over 510,000 new cases and more than 466,000 deaths annually. Despite advancements in oncology, treatment options for patients diagnosed with advanced stage disease remain disappointingly limited, with a five-year survival rate falling below 10%. This alarming statistic underscores the critical need for new and more effective therapeutic options for this aggressive disease.

The upcoming Phase Ib study is a continuation of previous successful collaborations between TFS and Oncomatryx. Their earlier trial evaluated OMTX705 both as a monotherapy and in combination with pembrolizumab, a well-known immune checkpoint inhibitor, for patients with advanced solid tumors. The promising results obtained from that initial trial have laid a strong foundation for this next phase of development and showcased Oncomatryx’s continuous focus on therapeutic performance, deep expertise, and specialization in oncology.

Kris O'Brien, Vice President of Oncology and Rare Diseases at TFS, expressed that this ongoing collaboration signifies their mutual commitment to accelerating the development of innovative therapies to combat challenging cancers like pancreatic adenocarcinoma. He emphasized TFS’s extensive therapeutic knowledge and operational agility, which are vital in propelling promising science in such urgent areas of need.

Laureano Simón, CEO of Oncomatryx, remarked on the excitement surrounding the new phase of clinical development for OMTX705. He highlighted TFS’s role as a reliable and expert partner, which is crucial for their scientific advancements that aim to benefit patients desperately needing new options.

With over twenty years of experience in oncology research, TFS has been actively involved in supporting clinical trials pertaining to solid tumors, hematologic malignancies, and rare cancers. Their unwavering focus on agility, scientific rigor, and a global reach has allowed them to effectively manage numerous early and late-stage oncology programs, guiding projects from conceptualization all the way to clinical application. Through long-term partnerships, such as this recent collaboration with Oncomatryx, TFS continues to provide tailored clinical solutions that advance science with the ultimate goal of improving patient lives worldwide.

The program for OMTX705 has gained momentum, especially after a robust fundraising effort of €25 million completed late in 2024. Moreover, Phase I clinical data from this project are expected to be presented at major oncology conferences throughout 2025, further enhancing its profile as a promising new approach for tackling difficult-to-treat tumors like pancreatic adenocarcinoma.

About TFS HealthScience

TFS HealthScience is an international Contract Research Organization that partners with biotechnology and pharmaceutical companies to advance innovative treatments and improve patient outcomes. Present in 40 countries, TFS and its strategic partners offer customized resource solutions and clinical development services in specialized therapeutic areas such as dermatology, internal medicine, neuroscience, oncology, and ophthalmology. With a focus on empowering partners and enriching lives, TFS provides flexible solutions that combine global reach with the adaptability and responsiveness characteristic of a mid-sized CRO.

About Oncomatryx

Oncomatryx has developed an exclusive platform of antibody-drug conjugates targeting cancer-associated fibroblasts within the microenvironment of metastatic solid tumors. Their pioneering ADCs are developed in collaboration with prestigious universities, hospitals, and research centers across both the United States and Europe. Clinical results from the Phase I trial of OMTX705, a new ADC targeting fibroblast activation protein in cancer-associated fibroblasts, will be presented at major oncology conferences throughout 2025.